Ranolazine Shortens Repolarization in Patients with Sustained Inward Sodium Current Due to Type-3 Long-QT Syndrome

Overview

Journal J Cardiovasc Electrophysiol

Specialties Cardiology & Vascular Diseases
Physiology

Date 2008 Jul 30

PMID 18662191

Citations 91

Authors

Arthur J Moss

Wojciech Zareba

Karl Q Schwarz

Spencer Rosero

Scott McNitt

Jennifer L Robinson

Affiliations

Soon will be listed here.

Abstract

Introduction: One form of the hereditary long-QT syndrome, LQT3-Delta KPQ, is associated with sustained inward sodium current during membrane depolarization. Ranolazine reduces late sodium channel current, and we hypothesized that ranolazine would have beneficial effects on electrical and mechanical cardiac function in LQT3 patients with the SCN5A-DeltaKPQ mutation.

Methods: We assessed the effects of 8-hour intravenous ranolazine infusions (45 mg/h for 3 hours followed by 90 mg/h for 5 hours) on ventricular repolarization and myocardial relaxation in 5 LQT3 patients with the SCN5A-Delta KPQ mutation. Changes in electrocardiographic repolarization parameters from before to during ranolazine infusion were evaluated by time-matched, paired t-test analyses. Cardiac ultrasound recordings were obtained before ranolazine infusion and just before completion of the 8-hour ranolazine infusion.

Results: Ranolazine shortened QTc by 26 +/- 3 ms (P < 0.0001) in a concentration-dependent manner. At peak ranolazine infusion, there was a significant 13% shortening in left ventricular isovolumic relaxation time, a significant 25% increase in mitral E-wave velocity, and a meaningful 22% decrease in mitral E-wave deceleration time compared with the baseline. No adverse effects of ranolazine were observed in the study patients.

Conclusion: Ranolazine at therapeutic concentrations shortened a prolonged QTc interval and improved diastolic relaxation in patients with the LQT3-Delta KPQ mutation, a genetic disorder that is known to cause an increase in late sodium current.

Citing Articles

Ranolazine Unveiled: Rediscovering an Old Solution in a New Light.

De Santis G, De Ferrari T, Parisi F, Franzino M, Molinero A, Di Carlo A J Clin Med. 2024; 13(17).

PMID: 39274195 PMC: 11396555. DOI: 10.3390/jcm13174985.

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy.

Coleman J, Doste R, Beltrami M, Argiro A, Coppini R, Olivotto I Front Pharmacol. 2024; 15:1379236.

PMID: 38659580 PMC: 11039821. DOI: 10.3389/fphar.2024.1379236.

Management of patients with an electrical storm or clustered ventricular arrhythmias: a clinical consensus statement of the European Heart Rhythm Association of the ESC-endorsed by the Asia-Pacific Heart Rhythm Society, Heart Rhythm Society, and....

Lenarczyk R, Zeppenfeld K, Tfelt-Hansen J, Heinzel F, Deneke T, Ene E Europace. 2024; 26(4).

PMID: 38584423 PMC: 10999775. DOI: 10.1093/europace/euae049.

Management of hemodynamically stable wide QRS complex tachycardia in patients with implantable cardioverter defibrillators.

Regoli F, Cattaneo M, Kola F, Thartori A, Bytyci H, Saccarello L Front Cardiovasc Med. 2023; 9:1011619.

PMID: 36684577 PMC: 9846131. DOI: 10.3389/fcvm.2022.1011619.

Modeling incomplete penetrance in long QT syndrome type 3 through ion channel heterogeneity: an in silico population study.

Miller J, Moise N, Weinberg S Am J Physiol Heart Circ Physiol. 2022; 324(2):H179-H197.

PMID: 36487185 PMC: 10072004. DOI: 10.1152/ajpheart.00430.2022.

References

Sogaard P, Egeblad H, Pedersen A, Kim W, Kristensen B, Hansen P . Sequential versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging. Circulation. 2002; 106(16):2078-84. DOI: 10.1161/01.cir.0000034512.90874.8e. View

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of.... J Am Soc Echocardiogr. 2005; 18(12):1440-63. DOI: 10.1016/j.echo.2005.10.005. View

Antzelevitch C, Belardinelli L, Zygmunt A, Burashnikov A, Di Diego J, Fish J . Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004; 110(8):904-10. PMC: 1513623. DOI: 10.1161/01.CIR.0000139333.83620.5D. View

Schram G, Zhang L, Derakhchan K, Ehrlich J, Belardinelli L, Nattel S . Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol. 2004; 142(8):1300-8. PMC: 1575187. DOI: 10.1038/sj.bjp.0705879. View

Scirica B, Morrow D, Hod H, Murphy S, Belardinelli L, Hedgepeth C . Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less.... Circulation. 2007; 116(15):1647-52. DOI: 10.1161/CIRCULATIONAHA.107.724880. View

Ruan Y, Liu N, Bloise R, Napolitano C, Priori S . Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation. 2007; 116(10):1137-44. DOI: 10.1161/CIRCULATIONAHA.107.707877. View

Moss A, Windle J, Hall W, Zareba W, Robinson J, McNitt S . Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol. 2005; 10(4 Suppl):59-66. PMC: 6932190. DOI: 10.1111/j.1542-474X.2005.00077.x. View

Song Y, Shryock J, Wagner S, Maier L, Belardinelli L . Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006; 318(1):214-22. DOI: 10.1124/jpet.106.101832. View

Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt A, Burashnikov A . Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther. 2004; 9 Suppl 1:S65-83. DOI: 10.1177/107424840400900106. View

10.

Song Y, Shryock J, Wu L, Belardinelli L . Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004; 44(2):192-9. DOI: 10.1097/00005344-200408000-00008. View

11.

Wu L, Shryock J, Song Y, Li Y, Antzelevitch C, Belardinelli L . Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004; 310(2):599-605. DOI: 10.1124/jpet.104.066100. View

12.

Bennett P, Yazawa K, Makita N, George Jr A . Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995; 376(6542):683-5. DOI: 10.1038/376683a0. View

13.

Imahashi K, Kusuoka H, Hashimoto K, YOSHIOKA J, Yamaguchi H, Nishimura T . Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res. 1999; 84(12):1401-6. DOI: 10.1161/01.res.84.12.1401. View

14.

Fredj S, Sampson K, Liu H, Kass R . Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006; 148(1):16-24. PMC: 1617037. DOI: 10.1038/sj.bjp.0706709. View

15.

Windle J, Geletka R, MOSS A, Zareba W, Atkins D . Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvasive Electrocardiol. 2001; 6(2):153-8. PMC: 7027642. DOI: 10.1111/j.1542-474x.2001.tb00100.x. View

16.

MOSS A, Schwartz P, Crampton R, Tzivoni D, Locati E, MacCluer J . The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991; 84(3):1136-44. DOI: 10.1161/01.cir.84.3.1136. View